Sociedad Americana de Hirudoterapia

Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Research article published in Chest (2012)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Practice guidelineEnsayos clínicosDesarrollo de fármacosDouketis et al. · Chest, 2012

Abstract

BACKGROUND: This guideline addresses the management of patients who are receiving anticoagulant or antiplatelet therapy and require an elective surgery or procedure. METHODS: The methods herein follow those discussed in the Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines article of this supplement. RESULTS: In patients requiring vitamin K antagonist (VKA) interruption before surgery, we recommend stopping VKAs 5 days before surgery instead of a shorter time before surgery (Grade 1B). In patients with a mechanical heart valve, atrial fibrillation, or VTE at high risk for thromboembolism, we suggest bridging anticoagulation instead of no bridging during VKA interruption (Grade 2C); in patients at low risk, we suggest no bridging instead of bridging (Grade 2C). In patients who require a dental procedure, we suggest continuing VKAs with an oral prohemostatic agent or stopping VKAs 2 to 3 days before the procedure instead of alternative strategies (Grade 2C). In moderate- to high-risk patients who are receiving acetylsalicylic acid (ASA) and require noncardiac surgery, we suggest continuing ASA around the time of surgery instead of stopping ASA 7 to 10 days before surgery (Grade 2C). In patients with a coronary stent who require surgery, we recommend deferring surgery > 6 weeks after bare-metal stent placement and > 6 months after drug-eluting stent placement instead of undertaking surgery within these time periods (Grade 1C); in patients requiring surgery within 6 weeks of bare-metal stent placement or within 6 months of drug-eluting stent placement, we suggest continuing antiplatelet therapy perioperatively instead of stopping therapy 7 to 10 days before surgery (Grade 2C). CONCLUSIONS: Perioperative antithrombotic management is based on risk assessment for thromboembolism and bleeding, and recommended approaches aim to simplify patient management and minimize adverse clinical outcomes.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticlePractice Guideline
Indexed MeSH termsAngioplasty, Balloon, CoronaryAspirinAtrial FibrillationDrug Administration ScheduleElective Surgical ProceduresEvidence-Based MedicineFibrinolytic AgentsHeart Valve ProsthesisHumansPerioperative CarePlatelet Aggregation InhibitorsPostoperative Complications

Resumen

This guideline addresses the management of patients who are receiving anticoagulant or antiplatelet therapy and require an elective surgery or procedure. The methods herein follow those discussed in the Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines.

Por qué esto importa para la hirudoterapia

Esta guía basada en la evidencia del American College of Chest Physicians, en su 9.ª edición, aborda cómo manejar a los pacientes que reciben terapia anticoagulante o antiagregante y necesitan cirugía electiva; recomienda (entre otras declaraciones graduadas) suspender los antagonistas de la vitamina K 5 días antes de la cirugía y administrar anticoagulación puente solo en los pacientes con alto riesgo tromboembólico. Para la hirudoterapia, proporciona un fundamento esencial de seguridad en el contexto clínico: dado que la terapia con sanguijuelas introduce hirudina y otros componentes anticoagulantes/antiagregantes del secretoma y produce exudación prolongada de la herida, el mismo marco de riesgo hemorrágico frente a tromboembólico perioperatorio que estas guías formalizan es el marco que el clínico debe aplicar antes de combinar la aplicación de sanguijuelas con cirugía o con fármacos antitrombóticos sistémicos. Advertencia: se trata de una guía de práctica clínica sobre terapia antitrombótica farmacológica y no estudia ni menciona la hirudoterapia; muchas de sus recomendaciones tienen una certeza débil (Grado 2C) y aporta contexto en lugar de respaldar el tratamiento con sanguijuelas.

Citación

Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Douketis et al. · Chest, 2012

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.